Endocrinology

Thyroid Cancer

Questions discussed in this category

What factors aside from progression do you consider most important in determining whether a patient with metastatic papillary thyroid carcinoma is radioactive iodine refractory?

What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?

1 Answer available

How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?

2 Answers available

Is dosimetry more important than preparation (ie rhTSH versus THW) when treating thyroid cancer with radioactive iodine therapy?

1 Answer available

What is the role of radiation therapy for an elderly patient with medullary thyroid cancer who is not a surgical candidate?

What techniques and doses would you prescribe to the primary and regional nodes?

1 Answer available

When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?

1 Answer available

What is the next step in management of a thyroid nodule that was biopsied and classified as Bethesda III, but Afirma genetic testing reveals parathyroid signature?

Patient does not have hypercalcemia.

2 Answers available

When would you offer radiation for poorly differentiated thyroid cancer?

3 Answers available

How would you approach patient with metastatic anaplastic thyroid cancer with NGS revealing only ARID1A mutation?

1 Answer available

Papers discussed in this category

Cancer discovery, 2015-07

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

J Immunother Cancer,

alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.

Related Topics in Endocrinology